论文部分内容阅读
随着化疗药物的不断更新,急性白血病的治疗有了显著的进展。但大剂量化疗可导致患者骨髓严重抑制和全身衰竭,同时因多种药物所产生的耐药性,急性白血病化疗后的复发率仍然很高,患者长期存活者也不多。因而使其应用受到了限制。近年来,由于组织相溶性配型技术和造血干细胞研究的进展,造血组织的移植取得了可喜的成果。现已知,造血干细胞是造血组织移植中起主要作用的细胞类型。除外周血有少量造血干细胞外,主要存在于骨髓和胎肝中。骨髓移植或胎肝输注的本质,就是造血干细胞的移植。由于供体或未受肿瘤细胞侵犯的骨髓中含有造血干细胞,可在患者骨髓造血微环境中增殖,故可重建体内正常造血功能,并有效地防止严重
With the continuous update of chemotherapy drugs, the treatment of acute leukemia has made significant progress. However, high-dose chemotherapy can lead to severe bone marrow suppression and systemic failure in patients with resistance due to a variety of drugs, the recurrence rate of acute leukemia after chemotherapy is still high, patients are not long-term survivors. Thus has restricted its application. In recent years, the transplantation of hematopoietic tissue has achieved gratifying results due to the development of tissue compatibility matching technology and hematopoietic stem cell research. It is known that hematopoietic stem cells are a type of cell that plays a major role in hematopoietic tissue transplantation. In addition to a small amount of peripheral blood hematopoietic stem cells, mainly in the bone marrow and fetal liver. The essence of bone marrow transplantation or fetal liver infusion is the transplantation of hematopoietic stem cells. Since the donor or non-tumor-infiltrated bone marrow contains hematopoietic stem cells that proliferate in the hematopoietic microenvironment of the patient’s bone marrow, normal hematopoietic function in the body can be reconstructed and the severity is effectively prevented